Gerresheimer (GXI) AGM 2026 summary

Opening remarks and agenda

• Key topics included transparency, company stabilization, compliance, and future orientation.

Board and executive committee updates

• Uwe Röhrhoff ended his interim mandate after stabilizing the company and setting its future direction.

• Leadership continuity ensured with a dual executive structure focused on transformation.

Financial performance review

• Revenue for 2024 corrected to €1.991 billion, with adjusted EBITDA at €388 million after internal investigations and corrections.

• 2025 revenue rose to €2.321 billion (+17%), mainly due to Bormioli Pharma acquisition; adjusted EBITDA slightly declined to €384 million.

• Plastics & Devices saw strong demand for drug delivery devices, while Primary Packaging Glass experienced declines due to weak demand and operational issues.

• Q1 2026 showed slight revenue growth and a significant improvement in free cash flow, driven by strict capital and inventory management.